Studies on the stability of VIII:C during the manufacture of a factor VIII concentrate for clinical use |
| |
| Authors: | P R Foster I H Dickson T A McQuillan C V Prowse F E Boulton P Greedharry A L Bloom |
| |
| Affiliation: | Scottish National Blood Transfusion Service, Protein Fractionation Centre, Edinburgh, UK. |
| |
| Abstract: | The stability of VIII:C was investigated by monitoring samples taken at different points from a routine process for the manufacture of factor VIII concentrate and by examining the stabilising influence of a number of product formulations. Loss of VIII:C over process-finishing procedures (formulation, 0.22 micron filtration, dispensing) was associated with a citrate-induced inactivation which could be prevented by controlling the ionised calcium concentration of the solution. These results were obtained using a one-stage clotting assay but were not observed using a two-stage assay. No evidence for activation was found in vitro (e.g. by FPA generation and VIII:C stability) and the yield increase suggested by the one-stage assay was supported by results from a controlled clinical evaluation. |
| |
| Keywords: | |
|
|
